24/7 Market News Snapshot 26 February, 2025 – Cognition Therapeutics, Inc. Common Stock (NASDAQ:CGTX)

February 26, 2025

DENVER, Colo., 26 February, 2025 (247marketnews.com) – (NASDAQ:CGTX) are discussed in this article.
Cognition Therapeutics, Inc. has experienced a significant surge in stock price, rising 28.73% to $0.665, with an impressive trading volume of 9.28 million shares in pre-market activity. This increase reflects heightened investor enthusiasm possibly linked to recent advancements in clinical trials involving its lead candidate, zervimesine (CT1812).

In an encouraging development, the company reported promising outcomes from their ongoing MAGNIFY Phase 2 trial, which evaluates zervimesine as a treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The recent masked data analysis indicated that participants who received zervimesine for at least six months experienced a slower progression of lesion growth compared to those on a placebo. The study, which aims to enroll 100 participants, is expected to culminate with final visits by February 2025, with comprehensive one-year dosing data anticipated for release in the second quarter of 2025.

Cognition is capitalizing on the momentum from the MAGNIFY trial, having preserved financial resources for future initiatives following the positive results. The company also recently announced successful outcomes from its Phase 2 SHIMMER study, which explored zervimesine in patients with mild-to-moderate dementia with Lewy bodies (DLB). The study met primary safety and tolerability endpoints while showcasing notable efficacy across various neuropsychiatric measures.

In addition to GA and DLB, Cognition Therapeutics is actively investigating zervimesine’s application in Alzheimer’s disease, with favorable results emerging from the Phase 2 SHINE study. As the company prepares for end-of-Phase 2 discussions with regulatory authorities, optimism grows around the therapeutic potential of zervimesine. The commitment of Cognition Therapeutics to developing innovative small molecule therapies reflects its focus on addressing the urgent needs of patients affected by neurodegenerative disorders. Further updates are anticipated as the clinical developments proceed.

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.